VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects who, in the opinion of the investigator,  │ Subjects who, in the opinion of the investigator,  │     100 │
│ can and will comply with the requirements of the   │ can and will comply with the requirements of the   │         │
│ protocol                                           │ protocol                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent obtained from the subject │ Written informed consent obtained from the subject │     100 │
│ prior to performing any study specific procedure   │ prior to performing any study specific procedure   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A male or female between, and including, 18 and 50 │ A male or female between, and including, 18 and 50 │     100 │
│ years of age at the time of the first study visit  │ years of age at the time of the first study visit  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Healthy subjects as established by medical history │ Healthy subjects as established by medical history │     100 │
│ and clinical examination before entering into the  │ and clinical examination before entering into the  │         │
│ study. Healthy subjects with no medical conditions │ study. Healthy subjects with no medical conditions │         │
│ that, in the opinion of the investigator, prevents │ that, in the opinion of the investigator, prevents │         │
│ the subject from participating in the study        │ the subject from participating in the study        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects of non-childbearing potential may  │ Female subjects of non-childbearing potential may  │     100 │
│ be enrolled in the study. Non-childbearing         │ be enrolled in the study. Non-childbearing         │         │
│ potential is defined as pre-menarche, current      │ potential is defined as pre-menarche, current      │         │
│ bilateral tubal ligation or occlusion,             │ bilateral tubal ligation or occlusion,             │         │
│ hysterectomy, bilateral ovariectomy or post-       │ hysterectomy, bilateral ovariectomy or post-       │         │
│ menopause                                          │ menopause                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ has practiced adequate contraception for 30 days   │ has practiced adequate contraception for 30 days   │     100 │
│ prior to vaccination, and                          │ prior to vaccination, and                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ has a negative pregnancy test on the day of        │ has a negative pregnancy test on the day of        │     100 │
│ vaccination and                                    │ vaccination and                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ has agreed to continue adequate contraception      │ has agreed to continue adequate contraception      │     100 │
│ during the entire treatment period and for 1       │ during the entire treatment period and for 1       │         │
│ month, after completion of the vaccination series  │ month, after completion of the vaccination series  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Progressive, unstable or uncontrolled clinical     │ Progressive, unstable or uncontrolled clinical     │     100 │
│ conditions                                         │ conditions                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypersensitivity, including allergy, to any        │ Hypersensitivity, including allergy, to any        │     100 │
│ component of vaccines, medicinal products or       │ component of vaccines, medicinal products or       │         │
│ medical equipment whose use is foreseen in this    │ medical equipment whose use is foreseen in this    │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical conditions representing a                 │ Clinical conditions representing a                 │     100 │
│ contraindication to intramuscular vaccination and  │ contraindication to intramuscular vaccination and  │         │
│ blood draws                                        │ blood draws                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical conditions                                │ Clinical conditions                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic administration of corticosteroids         │ Systemic administration of corticosteroids         │     100 │
│ (PO/IV/IM) within 90 days prior to informed        │ (PO/IV/IM) within 90 days prior to informed        │         │
│ consent                                            │ consent                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of antineoplastic and               │ Administration of antineoplastic and               │     100 │
│ immunomodulating agents or radiotherapy within 90  │ immunomodulating agents or radiotherapy within 90  │         │
│ days prior to informed consent                     │ days prior to informed consent                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received immunoglobulins or any blood products     │ Received immunoglobulins or any blood products     │     100 │
│ within 180 days prior to informed consent          │ within 180 days prior to informed consent          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received an investigational or non-registered      │ Received an investigational or non-registered      │     100 │
│ medicinal product within 30 days prior to informed │ medicinal product within 30 days prior to informed │         │
│ consent                                            │ consent                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other clinical condition that, in the opinion  │ Any other clinical condition that, in the opinion  │     100 │
│ of the investigator, might pose additional risk to │ of the investigator, might pose additional risk to │         │
│ the subject due to participation in the study      │ the subject due to participation in the study      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any history of meningococcal vaccination or        │ Any history of meningococcal vaccination or        │     100 │
│ meningococcal and gonorrhoea diseases              │ meningococcal and gonorrhoea diseases              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Enrolment in any activity requiring a blood        │ Enrolment in any activity requiring a blood        │     100 │
│ donation greater than 50 mL during the period      │ donation greater than 50 mL during the period      │         │
│ starting 30 days before the first study visit (Day │ starting 30 days before the first study visit (Day │         │
│ -83, Day -60 or Day -30) or for the duration of    │ -83, Day -60 or Day -30) or for the duration of    │         │
│ the study period                                   │ the study period                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of long-acting immune-modifying     │ Administration of long-acting immune-modifying     │     100 │
│ drugs at any time during the study period          │ drugs at any time during the study period          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with blood disorders                      │ Subjects with blood disorders                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a history of difficulty in providing │ Subjects with a history of difficulty in providing │     100 │
│ blood samples                                      │ blood samples                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any antibiotic intake 7 days prior to blood        │ Any antibiotic intake 7 days prior to blood        │     100 │
│ collection                                         │ collection                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who lost \>200 mL during a single         │ Subjects who lost >200 mL during a single          │     100 │
│ apheresis or who lost red blood cells on more than │ apheresis or who lost red blood cells on more than │         │
│ one occasion during apheresis within the previous  │ one occasion during apheresis within the previous  │         │
│ 60 days                                            │ 60 days                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concurrently participating in another clinical     │ Concurrently participating in another clinical     │     100 │
│ study, at any time during the study period, in     │ study, at any time during the study period, in     │         │
│ which the subject has been or will be exposed to   │ which the subject has been or will be exposed to   │         │
│ an investigational or a non-investigational        │ an investigational or a non-investigational        │         │
│ vaccine/product                                    │ vaccine/product                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing anaemia as indicated by haemoglobin values │ Ongoing anaemia as indicated by haemoglobin values │     100 │
│ below the lower limit of the laboratory-specified  │ below the lower limit of the laboratory-specified  │         │
│ reference range. If the finger prick method        │ reference range. If the finger prick method        │         │
│ demonstrates an anaemia, no further protocol       │ demonstrates an anaemia, no further protocol       │         │
│ procedures will be performed, and the subject will │ procedures will be performed, and the subject will │         │
│ be referred for appropriate medical management.    │ be referred for appropriate medical management.    │         │
│ The subject may participate in this study          │ The subject may participate in this study          │         │
│ following therapy and evidence that the anaemia    │ following therapy and evidence that the anaemia    │         │
│ has been resolved                                  │ has been resolved                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of any reaction or hypersensitivity likely │ History of any reaction or hypersensitivity likely │     100 │
│ to be exacerbated by any component of the vaccines │ to be exacerbated by any component of the vaccines │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating female                       │ Pregnant or lactating female                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female planning to become pregnant or planning to  │ Female planning to become pregnant or planning to  │     100 │
│ discontinue contraceptive precautions              │ discontinue contraceptive precautions              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any confirmed or suspected immunosuppressive or    │ Any confirmed or suspected immunosuppressive or    │     100 │
│ immunodeficiency condition based on medical        │ immunodeficiency condition based on medical        │         │
│ history and physical examination                   │ history and physical examination                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Family history of congenital or hereditary         │ Family history of congenital or hereditary         │     100 │
│ immunodeficiency                                   │ immunodeficiency                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serious chronic illness                            │ Serious chronic illness                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of chronic alcohol consumption and/or drug │ History of chronic alcohol consumption and/or drug │     100 │
│ abuse                                              │ abuse                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must weigh at least 110 pounds (50 kg),   │ Subjects must weigh at least 110 pounds (50 kg),   │      99 │
│ but not to present obesity (BMI \< 32kg/m2)        │ but not to present obesity (BMI < 32kg/m2)         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who donated \>450 mL of blood within 60   │ Subjects who donated >450 mL of blood within 60    │      99 │
│ days prior to any blood collection visits          │ days prior to any blood collection visits          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                      │   Score │
╞══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 50 Years                │ History of chronic alcohol consumption and/or drug │      34 │
│                                                  │ abuse                                              │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                │ History of chronic alcohol consumption and/or drug │      36 │
│                                                  │ abuse                                              │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal function of the immune system resulting │ Administration of long-acting immune-modifying     │      47 │
│ from                                             │ drugs at any time during the study period          │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female subjects of childbearing potential may be │ Female subjects of non-childbearing potential may  │      52 │
│ enrolled in the study, if the subject            │ be enrolled in the study. Non-childbearing         │         │
│                                                  │ potential is defined as pre-menarche, current      │         │
│                                                  │ bilateral tubal ligation or occlusion,             │         │
│                                                  │ hysterectomy, bilateral ovariectomy or post-       │         │
│                                                  │ menopause                                          │         │
╘══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 94.02564102564102
OverAll Ratio: 95.51282051282051
